Pitcairn Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Pitcairn Wealth Advisors's REGN Position: Q2 2026 in Review
Pitcairn Wealth Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 4.1% in Q2 2026, selling an estimated $30.6K and leaving 1,057 shares worth $659K. The position accounts for 0.07% of the portfolio, ranked #150.
Pitcairn Wealth Advisors first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $851K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Pitcairn Wealth Advisors held 1,057 shares of Regeneron Pharmaceuticals worth $659K as of Q2 2026.
- Pitcairn Wealth Advisors sold 45 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $30.6K.
- Regeneron Pharmaceuticals made up 0.07% of Pitcairn Wealth Advisors's portfolio in Q2 2026, its #150 holding.
- Pitcairn Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- Pitcairn Wealth Advisors's Regeneron Pharmaceuticals position peaked at $851K in Q1 2026.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Pitcairn Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.